Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Leadartis
Pamplona, Navarra, Spainleadartis.com ↗
- Ownership
- Private
- Employees
- ~9
- Development stage
- Preclinical
01
Overview
Leadartis has developed a novel class of bispecific/multispecific Fc-less antibodies called Trimerbodies. Their lead compound LEAD‑452—a conditional agonist targeting both EGFR and the immune co-stimulatory receptor 4‑1BB—has demonstrated superior safety/pharmacokinetics in non-human primate studies with no adverse events. The company claims a greater therapeutic window compared to competitors’ formats. LEAD‑452 is ready for clinical manufacturing and first-in-human Phase I basket study across multiple advanced cancer indications.
- Therapeutic areas
- OncologyGastroenterology
- Modalities
- Bispecific antibodiesMultispecific antibodiesSingle-chain FV antibody fragments
- Industry
- Biotech
Beyond the preview
Go deeper on Leadartis.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Leadartis.